The genetic landscape of the epileptic encephalopathies of infancy and childhood

The Lancet Neurology

Volumn 15, Issue 3, 2016, Pages 304-316

  McTague, Amy ^a,b   Howell, Katherine B ^c,d,e   Cross, J Helen ^a,b   Kurian, Manju A ^a,b   Scheffer, Ingrid E ^c,d,f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^f FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN FUNCTION; CHILD; COPY NUMBER VARIATION; DISEASE SEVERITY; GENE; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOTYPE; HEREDITY; HUMAN; INFANT; INFANTILE SPASM; INHERITANCE; LENNOX GASTAUT SYNDROME; MOSAICISM; NEXT GENERATION SEQUENCING; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; RECESSIVE INHERITANCE; REVIEW; SCN1A GENE; SOMATIC MUTATION; BRAIN DISEASES; COMPLICATION; EPILEPSY; GENETICS; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

BRAIN DISEASES; CHILD; CHILD, PRESCHOOL; EPILEPSY; HUMANS; INFANT;

EID: 84948799490     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00250-1     Document Type: Review

References (111)

1. 1 Ohtahara, S, Ishida, T, Oka, E, Yamatogi, Y, Inoue, H, Kanda, S, On the specific age dependent epileptic syndrome: the early-infantile epileptic encephalopathy with suppression-bursts. No To Hattatsu 8 (1976), 270–280.
2. 2 Ohtahara, S, A study on the age dependent epileptic encephalopathy. No To Hattatsu 9 (1977), 2–21.
3. 3 Thomas, RH, Zhang, LM, Carvill, GL, et al., the EuroEPINOMICS RES Consortium. CHD2 myoclonic encephalopathy is frequently associated with self-induced seizures. Neurology 84 (2015), 951–958.
4. 4 Howell, KB, McMahon, JM, Carvill, GL, et al. SCN2A encephalopathy: a major cause of epilepsy of infancy with migrating focal seizures. Neurology 85 (2015), 958–966.
5. 5 Wirrell, EC, Grossardt, BR, Wong-Kisiel, LCL, Nickels, KC, Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: a population-based study. Epilepsy Res 95 (2011), 110–118.
6. 6 Eltze, CM, Chong, WK, Cox, T, et al. A population-based study of newly diagnosed epilepsy in infants. Epilepsia 54 (2013), 437–445.
7. 7 Cowan, LD, Hudson, LS, The epidemiology and natural history of infantile spasms. J Child Neurol 6 (1991), 355–364.
8. 8 Hurst, DL, Epidemiology of severe myoclonic epilepsy of infancy. Epilepsia 31 (1990), 397–400.
9. 9 Bayat, A, Hjalgrim, H, Møller, RS, The incidence of SCN1A-related Dravet syndrome in Denmark is 1:22,000: a population-based study from 2004 to 2009. Epilepsia 56 (2015), e36–e39.
10. 10 Berg, AT, Berkovic, SF, Brodie, MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51 (2010), 676–685.
11. 11 Camfield, PR, Definition and natural history of Lennox-Gastaut syndrome. Epilepsia 52:suppl 50 (2011), 3–9.
12. 12 Bureau, M, Genton, P, Dravet, C, et al. Epileptic syndromes in infancy, childhood and adolesence, 5th edn., 2012, John Libbey Eurotext, Montrouge, 157–173.
13. 13 Goldin, AL, Barchi, RL, Caldwell, JH, et al. Nomenclature of voltage-gated sodium channels. Neuron 28 (2000), 365–368.
14. 14 Weiss, LA, Escayg, A, Kearney, JA, et al. Sodium channels SCN1A, SCN2A and SCN3A in familial autism. Mol Psychiatry 8 (2003), 186–194.
15. 15 Bender, AC, Natola, H, Ndong, C, Holmes, GL, Scott, RC, Lenck-Santini, P-P, Focal Scn1a knockdown induces cognitive impairment without seizures. Neurobiol Dis 54 (2013), 297–307.
16. 16 Battaglia, D, Chieffo, D, Siracusano, R, et al. Cognitive decline in Dravet syndrome: is there a cerebellar role?. Epilepsy Res 106 (2013), 211–221.
17. 17 Yu, FH, Mantegazza, M, Westenbroek, RE, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 9 (2006), 1142–1149.
18. 18 Chieffo, D, Battaglia, D, Lettori, D, et al. Neuropsychological development in children with Dravet syndrome. Epilepsy Res 95 (2011), 86–93.
19. 19 Osborne, JP, Lux, AL, Edwards, SW, et al. The underlying etiology of infantile spasms (West syndrome): information from the United Kingdom Infantile Spasms Study (UKISS) on contemporary causes and their classification. Epilepsia 51 (2010), 2168–2174.
20. 20 Poduri, A, Evrony, GD, Cai, X, Walsh, CA, Somatic mutation, genomic variation, and neurological disease. Science, 341, 2013, 1237758.
21. 21 Poduri, A, Evrony, GD, Cai, X, et al. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 74 (2012), 41–48.
22. 22 Guerrini, R, Dobyns, WB, Malformations of cortical development: clinical features and genetic causes. Lancet Neurol 13 (2014), 710–726.
23. 23 Carvill, GL, Heavin, SB, Yendle, SC, et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet 45 (2013), 825–830.
24. 24 Carvill, GL, Regan, BM, Yendle, SC, et al. GRIN2A mutations cause epilepsy-aphasia spectrum disorders. Nat Genet 45 (2013), 1073–1076.
25. 25 Lesca, G, Rudolf, G, Bruneau, N, et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet 45 (2013), 1061–1066.
26. 26 Lemke, JR, Lal, D, Reinthaler, EM, et al. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. Nat Genet 45 (2013), 1067–1072.
27. 27 Allen, AS, Berkovic, SF, Cossette, P, et al. the Epi4K Consortium, the Epilepsy Phenome/Genome Project. De novo mutations in epileptic encephalopathies. Nature 501 (2013), 217–221.
28. 28 Veeramah, KR, Johnstone, L, Karafet, TM, et al. Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. Epilepsia 54 (2013), 1270–1281.
29. 29 Barcia, G, Fleming, MR, Deligniere, A, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet 44 (2012), 1255–1259.
30. 30 Claes, L, Del-Favero, J, Ceulemans, B, Lagae, L, Van Broeckhoven, C, De Jonghe, P, De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 68 (2001), 1327–1332.
31. 31 Mefford, HC, Yendle, SC, Hsu, C, et al. Rare copy number variants are an important cause of epileptic encephalopathies. Ann Neurol 70 (2011), 974–985.
32. 32 Itsara, A, Cooper, GM, Baker, C, et al. Population analysis of large copy number variants and hotspots of human genetic disease. Am J Hum Genet 84 (2009), 148–161.
33. 33 Saitsu, H, Kato, M, Mizuguchi, T, et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat Genet 40 (2008), 782–788.
34. 34 Rauch, A, Wieczorek, D, Graf, E, et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet 380 (2012), 1674–1682.
35. 35 Harkin, LA, McMahon, JM, Iona, X, et al., the Infantile Epileptic Encephalopathy Referral Consortium. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 130 (2007), 843–852.
36. 36 Depienne, C, Bouteiller, D, Keren, B, et al. Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females. PLoS Genet, 5, 2009, e1000381.
37. 37 Vadlamudi, L, Dibbens, LM, Lawrence, KM, et al. Timing of de novo mutagenesis—a twin study of sodium-channel mutations. N Engl J Med 363 (2010), 1335–1340.
38. 38 Makrythanasis, P, Antonarakis, SE, Pathogenic variants in non-protein-coding sequences. Clin Genet 84 (2013), 422–428.
39. 39 Gan, J, Qu, Y, Li, J, Zhao, F, Mu, D, An evaluation of the links between microRNA, autophagy, and epilepsy. Rev Neurosci 26 (2015), 225–237.
40. 40 Rahman, S, Mitochondrial disease and epilepsy. Dev Med Child Neurol 54 (2012), 397–406.
41. 41 Depienne, C, Trouillard, O, Gourfinkel-An, I, et al. Mechanisms for variable expressivity of inherited SCN1A mutations causing Dravet syndrome. J Med Genet 47 (2010), 404–410.
42. 42 Noebels, J, Pathway-driven discovery of epilepsy genes. Nat Neurosci 18 (2015), 344–350.
43. 43 Singh, R, Andermann, E, Whitehouse, WP, et al. Severe myoclonic epilepsy of infancy: extended spectrum of GEFS+?. Epilepsia 42 (2001), 837–844.
44. 44 Depienne, C, Arzimanoglou, A, Trouillard, O, et al. Parental mosaicism can cause recurrent transmission of SCN1A mutations associated with severe myoclonic epilepsy of infancy. Hum Mutat, 27, 2006, 389.
45. 45 Marini, C, Mei, D, Helen Cross, J, Guerrini, R, Mosaic SCN1A mutation in familial severe myoclonic epilepsy of infancy. Epilepsia 47 (2006), 1737–1740.
46. 46 Morimoto, M, Mazaki, E, Nishimura, A, et al. SCN1A mutation mosaicism in a family with severe myoclonic epilepsy in infancy. Epilepsia 47 (2006), 1732–1736.
47. 47 Lee, JH, Huynh, M, Silhavy, JL, et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet 44 (2012), 941–945.
48. 48 Jamuar, SS, Lam, A-TN, Kircher, M, et al. Somatic mutations in cerebral cortical malformations. N Engl J Med 371 (2014), 733–743.
49. v7.2 potassium channel subunits. Proc Natl Acad Sci USA 110 (2013), 4386–4391.
50. 50 Orhan, G, Bock, M, Schepers, D, et al. Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy. Ann Neurol 75 (2014), 382–394.
51. 51 Nakamura, K, Kato, M, Osaka, H, et al. Clinical spectrum of SCN2A mutations expanding to Ohtahara syndrome. Neurology 81 (2013), 992–998.
52. 52 Singh, NA, Pappas, C, Dahle, EJ, et al. A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet, 5, 2009, e1000649.
53. 53 Pettit, RE, Fenichel, GM, Benign familial neonatal seizures. Arch Neurol 37 (1980), 47–48.
54. 54 Singh, NA, Charlier, C, Stauffer, D, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 18 (1998), 25–29.
55. 55 Biervert, C, Steinlein, OK, Structural and mutational analysis of KCNQ2, the major gene locus for benign familial neonatal convulsions. Hum Genet 104 (1999), 234–240.
56. 56 Weckhuysen, S, Mandelstam, S, Suls, A, et al. KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Ann Neurol 71 (2012), 15–25.
57. 57 Weckhuysen, S, Ivanovic, V, Hendrickx, R, et al., the KCNQ2 Study Group. Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology 81 (2013), 1697–1703.
58. 58 Kato, M, Yamagata, T, Kubota, M, et al. Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation. Epilepsia 54 (2013), 1282–1287.
59. 59 Zuberi, SM, Brunklaus, A, Birch, R, Reavey, E, Duncan, J, Forbes, GH, Genotype-phenotype associations in SCN1A-related epilepsies. Neurology 76 (2011), 594–600.
60. 60 Scheffer, IE, Zhang, Y-H, Jansen, FE, Dibbens, L, Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus?. Brain Dev 31 (2009), 394–400.
61. 61 Coppola, G, Plouin, P, Chiron, C, Robain, O, Dulac, O, Migrating partial seizures in infancy: a malignant disorder with developmental arrest. Epilepsia 36 (1995), 1017–1024.
62. 62 McTague, A, Appleton, R, Avula, S, et al. Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrum. Brain 136 (2013), 1578–1591.
63. 63 Ohba, C, Kato, M, Takahashi, N, et al. De novo KCNT1 mutations in early-onset epileptic encephalopathy. Epilepsia 56 (2015), e121–e128.
64. 64 Møller, RS, Heron, SE, Larsen, LHG, et al. Mutations in KCNT1 cause a spectrum of focal epilepsies. Epilepsia 56 (2015), e114–e120.
65. 65 Heron, SE, Smith, KR, Bahlo, M, et al. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 44 (2012), 1188–1190.
66. 66 Derry, CP, Heron, SE, Phillips, F, et al. Severe autosomal dominant nocturnal frontal lobe epilepsy associated with psychiatric disorders and intellectual disability. Epilepsia 49 (2008), 2125–2129.
67. 67 Martin, HC, Kim, GE, Pagnamenta, AT, et al., the WGS500 Consortium. Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis. Hum Mol Genet 23 (2014), 3200–3211.
68. 68 Milligan, CJ, Li, M, Gazina, EV, et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol 75 (2014), 581–590.
69. 69 Strømme, P, Mangelsdorf, ME, Shaw, MA, et al. Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. Nat Genet 30 (2002), 441–445.
70. 70 Shoubridge, C, Fullston, T, Gécz, J, ARX spectrum disorders: making inroads into the molecular pathology. Hum Mutat 31 (2010), 889–900.
71. 71 Carvill, GL, Weckhuysen, S, McMahon, JM, et al. GABRA1 and STXBP1: novel genetic causes of Dravet syndrome. Neurology 82 (2014), 1245–1253.
72. 72 Doose, H, Myoclonic-astatic epilepsy. Epilepsy Res Suppl 6 (1992), 163–168.
73. 73 Mullen, SA, Marini, C, Suls, A, et al. Glucose transporter 1 deficiency as a treatable cause of myoclonic astatic epilepsy. Arch Neurol 68 (2011), 1152–1155.
74. 74 Michaud, JL, Lachance, M, Hamdan, FF, et al. The genetic landscape of infantile spasms. Hum Mol Genet 23 (2014), 4846–4858.
75. 75 Lund, C, Brodtkorb, E, Øye, AM, Røsby, O, Selmer, KK, CHD2 mutations in Lennox-Gastaut syndrome. Epilepsy Behav 33 (2014), 18–21.
76. 76 Fullston, T, Brueton, L, Willis, T, et al. Ohtahara syndrome in a family with an ARX protein truncation mutation (c.81C>G/p.Y27X). Eur J Hum Genet 18 (2010), 157–162.
77. 77 Kato, M, Das, S, Petras, K, et al. Mutations of ARX are associated with striking pleiotropy and consistent genotype-phenotype correlation. Hum Mutat 23 (2004), 147–159.
78. 78 Absoud, M, Parr, JR, Halliday, D, Pretorius, P, Zaiwalla, Z, Jayawant, S, A novel ARX phenotype: rapid neurodegeneration with Ohtahara syndrome and a dyskinetic movement disorder. Dev Med Child Neurol 52 (2010), 305–307.
79. 79 Touma, M, Joshi, M, Connolly, MC, et al. Whole genome sequencing identifies SCN2A mutation in monozygotic twins with Ohtahara syndrome and unique neuropathologic findings. Epilepsia 54 (2013), e81–e85.
80. 80 Saitsu, H, Kato, M, Osaka, H, et al. CASK aberrations in male patients with Ohtahara syndrome and cerebellar hypoplasia. Epilepsia 53 (2012), 1441–1449.
81. o subunit of heterotrimeric G proteins, cause epileptic encephalopathy. Am J Hum Genet 93 (2013), 496–505.
82. 82 Carvill, GL, McMahon, JM, Schneider, A, et al., the EuroEPINOMICS Rare Epilepsy Syndrome Myoclonic-Astatic Epilepsy & Dravet working group. Mutations in the GABA transporter SLC6A1 cause epilepsy with myoclonic-atonic seizures. Am J Hum Genet 96 (2015), 808–815.
83. 83 Paciorkowski, AR, Thio, LL, Rosenfeld, JA, et al. Copy number variants and infantile spasms: evidence for abnormalities in ventral forebrain development and pathways of synaptic function. Eur J Hum Genet 19 (2011), 1238–1245.
84. 84 Oliver, KL, Lukic, V, Thorne, NP, Berkovic, SF, Scheffer, IE, Bahlo, M, Harnessing gene expression networks to prioritize candidate epileptic encephalopathy genes. PLoS One, 9, 2014, e102079.
85. 85 EuroEPINOMICS-RES Consortium the Epilepsy Phenome/Genome Project, the Epi4K Consortium. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet 95 (2014), 360–370.
86. 86 Kitamura, K, Yanazawa, M, Sugiyama, N, et al. Mutation of ARX causes abnormal development of forebrain and testes in mice and X-linked lissencephaly with abnormal genitalia in humans. Nat Genet 32 (2002), 359–369.
87. 87 James, S, An American in Oz, 2014, Allen & Unwin, Sydney.
88. 88 Catarino, CB, Liu, JYW, Liagkouras, I, et al. Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology. Brain 134 (2011), 2982–3010.
89. 89 Brunklaus, A, Dorris, L, Ellis, R, et al. The clinical utility of an SCN1A genetic diagnosis in infantile-onset epilepsy. Dev Med Child Neurol 55 (2013), 154–161.
90. 90 Chiron, C, Dulac, O, The pharmacologic treatment of Dravet syndrome. Epilepsia 52:suppl 2 (2011), 72–75.
91. 91 Might, M, Wilsey, M, The shifting model in clinical diagnostics: how next-generation sequencing and families are altering the way rare diseases are discovered, studied, and treated. Genet Med 16 (2014), 736–737.
92. 92 Lemke, JR, Riesch, E, Scheurenbrand, T, et al. Targeted next generation sequencing as a diagnostic tool in epileptic disorders. Epilepsia 53 (2012), 1387–1398.
93. 93 Stitziel, NO, Kiezun, A, Sunyaev, S, Computational and statistical approaches to analyzing variants identified by exome sequencing. Genome Biol, 12, 2011, 227.
94. 94 Bentley, DR, Balasubramanian, S, Swerdlow, HP, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456 (2008), 53–59.
95. 95 Cai, X, Evrony, GD, Lehmann, HS, et al. Single-cell, genome-wide sequencing identifies clonal somatic copy-number variation in the human brain. Cell Reports 8 (2014), 1280–1289.
96. 96 Klepper, J, GLUT1 deficiency syndrome in clinical practice. Epilepsy Res 100 (2012), 272–277.
97. 97 Garin Shkolnik, T, Feuerman, H, Didkovsky, E, et al. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. JAMA Dermatol 150 (2014), 984–989.
98. 98 Lemke, JR, Hendrickx, R, Geider, K, et al. GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy. Ann Neurol 75 (2014), 147–154.
99. 99 Pierson, TM, Yuan, H, Marsh, ED, et al., the PhD for the NISC Comparative Sequencing Program. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol 1 (2014), 190–198.
100. 100 Bearden, D, Strong, A, Ehnot, J, DiGiovine, M, Dlugos, D, Goldberg, EM, Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol 76 (2014), 457–461.
101. 101 Mikati, MA, Jiang, Y-H, Carboni, M, et al. Quinidine in the treatment of KCNT1 positive epilepsies. Ann Neurol, 2015, 10.1002/ana.24520 published online Sept 15.
102. 102 Ma, C, Su, L, Seven, AB, Xu, Y, Rizo, J, Reconstitution of the vital functions of Munc18 and Munc13 in neurotransmitter release. Science 339 (2013), 421–425.
103. 103 Hussain, S, Developing a PPI inhibitor-based therapy for STXBP1 haploinsufficiency-associated epileptic disorders. Front Mol Neurosci, 7, 2014, 6.
104. 104 Azzarito, V, Long, K, Murphy, NS, Wilson, AJ, Inhibition of α-helix-mediated protein-protein interactions using designed molecules. Nat Chem 5 (2013), 161–173.
105. 105 Liu, Y, Lopez-Santiago, LF, Yuan, Y, et al. Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism. Ann Neurol 74 (2013), 128–139.
106. 106 Cirak, S, Arechavala-Gomeza, V, Guglieri, M, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378 (2011), 595–605.
107. 107 Huang, X, Tian, M, Hernandez, CC, Hu, N, Macdonald, RL, The GABRG2 nonsense mutation, Q40X, associated with Dravet syndrome activated NMD and generated a truncated subunit that was partially rescued by aminoglycoside-induced stop codon read-through. Neurobiol Dis 48 (2012), 115–123.
108. 108 Wykes, RC, Heeroma, JH, Mantoan, L, et al. Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Sci Transl Med, 4, 2012, 161ra152.
109. 109 Kullmann, DM, Schorge, S, Walker, MC, Wykes, RC, Gene therapy in epilepsy-is it time for clinical trials?. Nat Rev Neurol 10 (2014), 300–304.
110. 110 Kätzel, D, Nicholson, E, Schorge, S, Walker, MC, Kullmann, DM, Chemical-genetic attenuation of focal neocortical seizures. Nat Commun, 5, 2014, 3847.
111. 111 Matsa, E, Dixon, JE, Medway, C, et al. Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. Eur Heart J 35 (2014), 1078–1087.